Evaluation of Perioperative Risk Factors for Infection by Multidrug-Resistant Bacteria in Patients Undergoing Liver Transplantation.

IF 3 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES
Rafael Ramos Fernández, Alberto Calvo García, Ainhoa Fernández Yunkera, Silvia Ramos Cerro, Ignacio Garutti, Javier Hortal Iglesias, Patricia Muñoz García, Sergio García Ramos, Adoración Elvira Rodríguez, Mercedes Power Esteban, Patricia Duque González, Patricia Piñeiro
{"title":"Evaluation of Perioperative Risk Factors for Infection by Multidrug-Resistant Bacteria in Patients Undergoing Liver Transplantation.","authors":"Rafael Ramos Fernández, Alberto Calvo García, Ainhoa Fernández Yunkera, Silvia Ramos Cerro, Ignacio Garutti, Javier Hortal Iglesias, Patricia Muñoz García, Sergio García Ramos, Adoración Elvira Rodríguez, Mercedes Power Esteban, Patricia Duque González, Patricia Piñeiro","doi":"10.3390/jpm15060240","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Liver transplantation (LT) is a critical intervention for patients with end-stage liver disease. Infections caused by multidrug-resistant bacteria (MDRB) significantly worsen post-transplant outcomes. The main objective of this study was to analyze perioperative risk factors associated with MDRB infections within six months following LT. <b>Methods:</b> A retrospective analysis was conducted on 133 medical records of patients who underwent liver transplantation between October 2018 and May 2022. Data collected included the presence of MDRB colonization and infection, as well as various perioperative variables. These were analyzed to identify potential risk factors for MDRB infection and colonization. <b>Results:</b> Univariate analysis identified several perioperative variables associated with MDRB infection within six months after LT. Multivariate logistic regression revealed that pre-transplant MDRB colonization (OR 5.72, 95% CI 1.7-18.7, <i>p</i> = 0.005) and the requirement for dialysis during postoperative ICU stay (OR 6.42, 95% CI 1.7-23.4, <i>p</i> = 0.009) were independent risk factors for developing MDRB infections. MDRB infection occurred in 9.4% of patients and was not significantly associated with increased mortality (<i>p</i> = 0.126). <b>Conclusions:</b> These findings contribute to a better understanding of the epidemiology and pathophysiology of MDRB infections in the postoperative period of liver transplantation. This knowledge is essential for developing effective prevention and treatment strategies that may improve outcomes in this patient population.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 6","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12194424/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Personalized Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/jpm15060240","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Liver transplantation (LT) is a critical intervention for patients with end-stage liver disease. Infections caused by multidrug-resistant bacteria (MDRB) significantly worsen post-transplant outcomes. The main objective of this study was to analyze perioperative risk factors associated with MDRB infections within six months following LT. Methods: A retrospective analysis was conducted on 133 medical records of patients who underwent liver transplantation between October 2018 and May 2022. Data collected included the presence of MDRB colonization and infection, as well as various perioperative variables. These were analyzed to identify potential risk factors for MDRB infection and colonization. Results: Univariate analysis identified several perioperative variables associated with MDRB infection within six months after LT. Multivariate logistic regression revealed that pre-transplant MDRB colonization (OR 5.72, 95% CI 1.7-18.7, p = 0.005) and the requirement for dialysis during postoperative ICU stay (OR 6.42, 95% CI 1.7-23.4, p = 0.009) were independent risk factors for developing MDRB infections. MDRB infection occurred in 9.4% of patients and was not significantly associated with increased mortality (p = 0.126). Conclusions: These findings contribute to a better understanding of the epidemiology and pathophysiology of MDRB infections in the postoperative period of liver transplantation. This knowledge is essential for developing effective prevention and treatment strategies that may improve outcomes in this patient population.

肝移植患者多药耐药菌感染围手术期危险因素评价。
背景:肝移植(LT)是终末期肝病患者的关键干预措施。多药耐药细菌(MDRB)引起的感染显著恶化移植后的预后。本研究的主要目的是分析肝移植术后6个月内与MDRB感染相关的围手术期危险因素。方法:回顾性分析2018年10月至2022年5月期间133例肝移植患者的医疗记录。收集的数据包括MDRB定植和感染的存在,以及各种围手术期变量。对这些数据进行分析,以确定MDRB感染和定植的潜在危险因素。结果:单因素分析确定了移植后6个月内与MDRB感染相关的几个围手术期变量。多因素logistic回归显示,移植前MDRB定殖(OR 5.72, 95% CI 1.7-18.7, p = 0.005)和术后ICU住院期间透析需求(OR 6.42, 95% CI 1.7-23.4, p = 0.009)是发生MDRB感染的独立危险因素。9.4%的患者发生MDRB感染,与死亡率增加无显著相关性(p = 0.126)。结论:这些发现有助于更好地了解肝移植术后MDRB感染的流行病学和病理生理学。这些知识对于制定有效的预防和治疗策略至关重要,这些策略可能会改善这一患者群体的预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Personalized Medicine
Journal of Personalized Medicine Medicine-Medicine (miscellaneous)
CiteScore
4.10
自引率
0.00%
发文量
1878
审稿时长
11 weeks
期刊介绍: Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., pharmacogenomics/proteomics, systems biology). JPM recognizes that personalized medicine—the assessment of genetic, environmental and host factors that cause variability of individuals—is a challenging, transdisciplinary topic that requires discussions from a range of experts. For a comprehensive perspective of personalized medicine, JPM aims to integrate expertise from the molecular and translational sciences, therapeutics and diagnostics, as well as discussions of regulatory, social, ethical and policy aspects. We provide a forum to bring together academic and clinical researchers, biotechnology, diagnostic and pharmaceutical companies, health professionals, regulatory and ethical experts, and government and regulatory authorities.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信